CBIS Very Excited Over Federal Cannabis Legalization Efforts in U.S. House and Senate to Change Medical Cannabis Laws

U.S. Representative Scott Perry (R-PA) Introduces Bipartisan Amendment to Controlled Substances Act and U.S. Senator Rand Paul (R-KY) Seeks Rescheduling of Cannabis

July 30, 2014

COLORADO SPRINGS, Colo., July 29, 2014 /PRNewswire/ -- Cannabis Science, Inc. (CBIS), a U.S. Company specializing in cannabis formulation-based drug development and related consulting, is extremely excited to report federal cannabis legalization efforts in U.S. House and Senate to change medical cannabis laws across the country. This can be a major game changer for Cannabis Science's efforts to commence its cannabis treatments nationwide for a number of targeted critical ailments.

U.S. Representative Scott Perry's introduction of a bill, H.R. 5226, yesterday to remove therapeutic, low-THC, high-CBD cannabis oil from the relevant definitions of the federal Controlled Substances Act, thereby permitting treatment throughout the United States of seizure disorders with cannabis, while Cannabis Science has multiple formulations for multiple critical ailments to begin nationwide distribution through its state by state partners and ultimate FDA clinical trials. ( www.cannabisscience.com )

These are significant steps towards federal legalization with a widespread impact on the national status of medical cannabis use, which will enable Cannabis Science to move swiftly into a position of great strength to bring its proprietary cannabis formulations to market.

The three other sponsors of the bill include Representatives Dana Rohrabacher (R-CA), Representative Steve Cohen (D-TN), and Representative Paul Broun, MD (R-GA). 

The Company also commends U.S. Senator Rand Paul's new announcement to introduce a bill to reschedule cannabis from its Schedule 1 status under the Act and his recent legislative efforts to protect states that have legalized medical cannabis.

"After many successful medical cannabis initiatives on the state level, we are seeing federal lawmakers of both parties actively legislating for medical cannabis reform on a federal level to help patients.  Cannabis Science supports these federal efforts and calls on Members of Congress to examine and expand patient-based research and support these critical bills," said Chad S. Johnson, Esq., Director, COO and General Counsel, Cannabis Science, Inc.

These lawmakers add additional, active voices in Congress pressing for medical cannabis reform on a federal level.  Click here to read Representative Perry's official press release.

About Cannabis Science, Inc.
Cannabis Science, Inc., takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently, there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on skin cancers and neurological conditions.

Forward-Looking Statements
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as "anticipate," "seek," intend," "believe," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc., does not undertake any duty nor does it intend to update the results of these forward-looking statements.